Serum uric acid is associated with bone health in older men: A cross-sectional population-based study

Journal of Bone and Mineral Research

Volumn 26, Issue 5, 2011, Pages 955-964

  Nabipour, Iraj ^a   Sambrook, Philip N ^b   Blyth, Fiona M ^a,d   Janu, Margaret R ^c   Waite, Louise M ^a   Naganathan, Vasi ^a   Handelsman, David J ^a   Le Couteur, David G ^a   Cumming, Robert G ^a,d   Seibel, Markus J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c Department of Microbiology and Infectious Diseases   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

ANTIOXIDANT; BONE HEALTH; BONE MINERAL DENSITY; BONE TURNOVER; FRACTURE; URIC ACID

Indexed keywords

25 HYDROXYVITAMIN D; ALLOPURINOL; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; INDAPAMIDE; PARATHYROID HORMONE; TESTOSTERONE; THIAZIDE DIURETIC AGENT; URIC ACID; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CALCIUM BLOOD LEVEL; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OXIDATIVE STRESS; PARATHYROID HORMONE BLOOD LEVEL; POPULATION RESEARCH; URIC ACID BLOOD LEVEL; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL;

AGED; BONE AND BONES; BONE DENSITY; CROSS-SECTIONAL STUDIES; HEALTH; HIP; HUMANS; LINEAR MODELS; LUMBAR VERTEBRAE; MALE; ODDS RATIO; OSTEOPOROSIS; URIC ACID;

EID: 79955571128     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.286     Document Type: Article

References (63)

1. Edwards NL., The role of hyperuricemia and gout in kidney and cardiovascular disease. Cleve Clin J Med. 2008; 75: S13-16.
2. Mandell BF., Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008; 75: S5-8.
3. Edwards NL., The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009; 21: 132-137.
4. Lippi G, Montagnana M, Franchini M, Favaloro EJ, Targher G., The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta. 2008; 392: 1-7.
5. Holme I, Aasteveit AH, Hammar N, Jungner I, Walldius G., Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 mean and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med. 2009; 266: 558-570.
6. Bergamini C, Cicoira M, Rossi A, Vassanelli C., Oxidative stress and hyperuricaemia: pathophysiology, clinical relevance, and therapeutic implications in chronic heart failure. Eur J Heart Fail. 2009; 11: 444-452.
7. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P., Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000; 36: 1072-1078.
8. Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease ? Hypertens. 2003; 41: 1183-1190. (Pubitemid 36706063)
9. Men P, Punzo G., Uric acid: bystander or culprit in hypertension and progressive renal disease ? J Hypertens. 2008; 26: 2085-2092.
10. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA., Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum. 2009; 61: 885-892.
11. Dehghan A, van Hoek M, Sijbrands EJ, Hofman A, Witteman JC., High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care. 2008; 31: 361-362. (Pubitemid 351213351)
12. Kramer CK, von Mühlen D, Jassal SK, Barrett-Connor E., Serum uric acid levels improve prediction of incident type 2 diabetes in individuals with impaired fasting glucose: the Rancho Bernardo Study. Diabetes Care. 2009; 32: 1272-1273.
13. Puig JG, MartÃnez MA., Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol. 2008; 20: 187-191. (Pubitemid 351339891)
14. Nakagawa T, Cirillo P, Sato W, et al. The conundrum of hyperuricemia, metabolic syndrome, and renal disease. Intern Emerg Med. 2008; 3: 313-318.
15. Oda E, Kawai R, Sukumaran V, Watanabe K., Uric acid is positively associated with metabolic syndrome but negatively associated with diabetes in Japanese men. Intern Med. 2009; 48: 1785-1791.
16. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002; 40: 355-360. (Pubitemid 35006723)
17. Johnson RJ, Sautin YY, Oliver WJ, et al. Lessons from comparative physiology: could uric acid represent a physiologic alarm signal gone awry in western society ? J Comp Physiol B. 2009; 179: 67-76.
18. Ames BN, Cathcart R, Schwiers E, Hochstein P., Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981; 78: 6858-6862. (Pubitemid 12216861)
19. Glantzounis GK, Tsimoyiannis EC, Kappas AM, Galaris DA., Uric acid and oxidative stress. Curr Pharm Des. 2005; 11: 4145-4151. (Pubitemid 41672464)
20. Massa J, O'Reilly E, Munger KL, Delorenze GN, Ascherio A., Serum uric acid and risk of multiple sclerosis. J Neurol. 2009; 256: 1643-1648.
21. Andreadou E, Nikolaou C, Gournaras F, et al. Serum uric acid levels in patients with Parkinson's disease: their relationship to treatment and disease duration. Clin Neurol Neurosurg. 2009; 111: 724-728.
22. Keizman D, Ish-Shalom M, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress ? J Neurol Sci. 2009; 285: 95-99.
23. Euser SM, Hofman A, Westendorp RG, Breteler MM., Serum uric acid and cognitive function and dementia. Brain. 2009; 132 (Pt 2): 377-382.
24. Maggio D, Barabani M, Pierandrei M, et al. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab. 2003; 88: 1523-1527. (Pubitemid 36623364)
25. Sugiura M, Nakamura M, Ogawa K, Ikoma Y, Ando F, Yano M., Bone mineral density in post-menopausal female subjects is associated with serum antioxidant carotenoids. Osteoporos Int. 2008; 19: 211-219.
26. Sendur OF, Turan Y, Tastaban E, Serter M., Antioxidant status in patients with osteoporosis: a controlled study. Joint Bone Spine. 2009; 76: 514-518.
27. Sahni S, Hannan MT, Blumberg J, Cupples LA, Kiel DP, Tucker KL., Inverse association of carotenoid intakes with 4-y change in bone mineral density in elderly men and women: the Framingham Osteoporosis Study. Am J Clin Nutr. 2009; 89: 416-424.
28. Sánchez-Rodríguez MA, Ruiz-Ramos M, Correa-Muñoz E, Mendoza-NÃñez VM., Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskelet Disord. 2007; 8: 124.
29. Sahni S, Hannan MT, Gagnon D, et al. High vitamin C intake is associated with lower 4-year bone loss in elderly men. J Nutr. 2008; 138: 1931-1938.
30. Ostman B, Michaëlsson K, Helmersson J, et al. Oxidative stress and bone mineral density in elderly men: antioxidant activity of alpha-tocopherol. Free Radic Biol Med. 2009; 47: 668-673.
31. Cumming RG, Handelsman D, Seibel MJ, et al. Cohort Profile: the Concord Health and Ageing in Men Project (CHAMP). Int J Epidemiol. 2009; 38: 374-378.
32. Washburn RA, Smith KW, Jette AM, Janney CA., The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993; 46: 153-162. (Pubitemid 23092124)
33. Goldberg DM, Soleas GJ, Levesque M., Moderate alcohol consumption: the gentle face of Janus. Clin Biochem. 1999; 32: 505-518. (Pubitemid 30007762)
34. Tucker KL, Jugdaohsingh R, Powell JJ, et al. Effects of beer, wine, and liquor intakes on bone mineral density in older men and women. Am J Clin Nutr. 2009; 89: 1188-1196.
35. McMillan J, Beavis A, Jones FL., The AUSEI06 A new socioeconomic index for Australia. J Sociol. 2009; 45: 123-149.
36. Australian Bureau of Statistics. Standard Australian Classification of Countries (SACC), 2008, second ed. 1269.
37. Herrmann M, Seibel MJ., The amino- and carboxyterminal cross-linked telopeptides of collagen type I: a comparative review. Clin Chim Acta. 2008; 393: 57-5775.
38. Almeida M, Han L, Martin-Millan M, O'Brien C, Manolagas S., Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007; 282: 27298-27305. (Pubitemid 47501978)
39. Dalbeth N, Smith T, Nicolson B, et al. Enhanced osteoclastogenesis in patients with tophaceous gout: urate crystals promote osteoclast development through interactions with stromal cells. Arthritis Rheum. 2008; 58: 1854-1865. (Pubitemid 351847541)
40. Yoneda M, Takatsuki K, Tomita A., [Parathyroid function and uric acid metabolism]. Nippon Naibunpi Gakkai Zasshi. 1983; 59: 1738-1751.
41. Valdemarsson S, Lindblom P, Bergenfelz A., Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J Intern Med. 1998; 244: 241-249. (Pubitemid 28389661)
42. Dalbeth N, Horne A, Gamble G, et al. The effect of calcium supplementation on serum urate: analysis of a randomized controlled trial. Rheumatology (Oxf). 2009; 48: 195-197.
43. Kohri Takada M, Katoh Y, et al. Parathyroid hormone and electrolytes during long-term treatment with allopurinol and thiazide. Br J Urol. 1987; 59: 503-507. (Pubitemid 17075364)
44. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007; 357: 2028-2039. (Pubitemid 350106710)
45. Miller PD., Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008; 6: 12-16.
46. Miller PD, Schwartz E, Chen P, Misurski D, Krege J., Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2007; 18: 59-68. (Pubitemid 44885496)
47. Laspa E, Bastepe M, Jüppner H, Tsatsoulis A., Phenotypic and molecular genetic aspects of pseudohypoparathyroidism type Ib in a Greek kindred: evidence for enhanced uric acid excretion due to parathyroid hormone resistance. J Clin Endocrinol Metab. 2004; 89: 5942-5947. (Pubitemid 39628397)
48. Unluturk U, Harmanci A, Babaoglu M, et al. Molecular diagnosis and clinical characterization of pseudohypoparathyroidism type-Ib in a patient with mild Albright's hereditary osteodystrophy-like features, epileptic seizures, and defective renal handling of uric acid. Am J Med Sci. 2008; 336: 84-90.
49. Mount DB, Kwon CY, Zandi-Nejad K., Renal urate transport. Rheum Dis Clin North Am. 2006; 32: 313-331. (Pubitemid 43728821)
50. Le Couteur DG, Everitt A, Lebel M., The aging liver. Geriatr Aging. 2009; 12: 319-322.
51. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Yamakita J, Higashino K., Decreased serum concentrations of 1,25(OH)2-vitamin D3 in patients with gout. Adv Exp Med Biol. 1998; 431: 57-60. (Pubitemid 28236739)
52. Jarrar K, Amasheh R, Graef V, Weidner W., Relationship between 1,25-dihydroxyvitamin-D, calcium and uric acid in urinary stone formers. Urol Int. 1996; 56: 16-20. (Pubitemid 26018115)
53. Orwoll ES, Bell NH, Nanes M, et al. Collagen N-telopeptide excretion in men: the effects of age and intrasubject variability. J Clin Endocrinol Metab. 1998; 83: 3930-3935. (Pubitemid 28513575)
54. Holden CA, McLaclan RI, Pitts M, et al. Men in Australia Telephone Survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet. 2005; 366: 218-224. (Pubitemid 40981049)
55. Cauley JA, Fullman RL, Stone KL, et al. Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int. 2005; 16: 1525-1537. (Pubitemid 41790856)
56. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007; 16; 4: e297.
57. Benson K, Hartz AJ., A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000; 22; 342: 1878-1886. (Pubitemid 30419053)
58. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009; 76 (Suppl 113): S1.
59. Klawansky S, Komaroff E, Cavanaugh PF, et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003; 14: 570-576. (Pubitemid 36975556)
60. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K., Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int. 1999; 56: 1084-1093. (Pubitemid 29411737)
61. Albala C, Yáñez M, Devoto E, Sostin C, Zeballos L, Santos JL., Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord. 1996; 20: 1027-1032. (Pubitemid 26366457)
62. Ferrar L, Jiang G, Cawthon PM, et al. Identification of vertebral fracture and non-osteoporotic short vertebral height in men: the MrOS study. J Bone Miner Res. 2007; 22: 1434-1441. (Pubitemid 351339688)
63. Khosla S, Amin S, Orwoll E., Osteoporosis in men. Endocr Rev. 2008; 29: 441-464. (Pubitemid 351831508)